Viscosupplementation is a minimally invasive procedure that involves injection of the hyaluronic acid injected into a knee joint to promote better joint development and lubrication. It also helps in reducing pain, irritation and helps in improving osteoarthritis condition. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan that is distributed throughout the body in epithelial, connective tissues, and neural tissues. Increasing prevalence of osteoarthritis in people is expected to boost demand for the viscosupplementation products.
Restraints of the Europe Viscosupplementation Market
Major factors hampering the growth of the viscosupplementation market during the forecast period constitutes of high costs and side effect.
Key features of the study:
- This report provides in-depth analysis of the Europe viscosupplementation market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the Europe viscosupplementation market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Sanofi S.A., Anika Therapeutics, Inc., Seikagaku, Zimmer Biomet Holdings Inc., Meda AB (Mylan), Fidia Farmaceutici S.p.A., Bioventus LLC, Ferring B.V, Lifecore Biomedical, and LG Life Sciences.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The Europe viscosupplementation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
- Europe Viscosupplementation Market, By Type:
- Single Injection Cycle
- Three Injection Cycle
- Five Injection Cycle
- Europe Viscosupplementation Market, By End User:
- Europe Viscosupplementation Market, By Country:
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Nordic Countries
- Rest of Western Europe
- Eastern Europe
- Russia
- Rest of Eastern Europe
- Company Profiles
- Sanofi S.A.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Anika Therapeutics, Inc.
- Seikagaku Corporation
- Zimmer Biomet Holdings Inc.
- Meda AB (Mylan)
- Fidia Farmaceutici S.p.A.
- Bioventus LLC
- Ferring B.V
- Lifecore Biomedical
- LG Life Sciences
"*" marked represents similar segmentation in other categories in the respective section.